David A. Siegel Recursion Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 815,445 shares of RXRX stock, worth $3.38 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

815,445

Holding current value

$3.38 Million

% of portfolio

0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$4.52 - $6.54 $3.69 Million - $5.33 Million	815,445 New	815,445 $3.98 Million
Q1 2025 May 15, 2025	SELL	$5.29 - $10.87 $1.88 Million - $3.87 Million	-356,300 Reduced 78.87%	95,445 $504,000
Q4 2024 Feb 14, 2025	SELL	$5.7 - $8.27 $217,483 - $315,541	-38,155 Reduced 7.79%	451,745 $3.05 Million
Q3 2024 Nov 14, 2024	BUY	$5.92 - $8.6 $320,272 - $465,260	54,100 Added 12.41%	489,900 $3.23 Million
Q2 2024 Aug 14, 2024	BUY	$7.35 - $10.05 $1.84 Million - $2.52 Million	250,700 Added 135.44%	435,800 $3.27 Million
Q1 2024 May 15, 2024	BUY	$9.13 - $15.52 $1.4 Million - $2.38 Million	153,400 Added 483.91%	185,100 $1.85 Million
Q4 2023 Feb 14, 2024	BUY	$5.09 - $10.79 $161,353 - $342,043	31,700 New	31,700 $312,000
Q1 2023 May 15, 2023	BUY	$6.42 - $9.64 $98,868 - $148,456	15,400 New	15,400 $102,000
Q2 2022 Aug 15, 2022	SELL	$5.04 - $9.26 $202,104 - $371,326	-40,100 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.16 - $18.03 $247,016 - $723,003	40,100 New	40,100 $287,000

Others Institutions Holding RXRX

# of Institutions

365

Shares Held

304M

Call Options Held

7.56M

Put Options Held

4.72M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $747M
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account